Atricure announces launch of the cryosphere®+ probe for post-operative pain management

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management, and post-operative pain management, today announced that it has launched the cryosphere®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus atricure's legacy cryoshpere® device. the product is currently in an extended limited launch period in the united states, wit.
ATRC Ratings Summary
ATRC Quant Ranking